CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation

Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER)-positive breast cancer. However, tamoxifen resistance has become an insurmountable clinical challenge, and the underlying mechanisms are still poorly understood. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jun, Le, Kehao, Xu, Ming, Ming, Jie, Yang, Wen, Zhang, Qiulei, Lu, Linlin, Xi, Zihan, Ruan, Shengnan, Huang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311345/
https://www.ncbi.nlm.nih.gov/pubmed/32691010
http://dx.doi.org/10.1016/j.omto.2020.06.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311345/
https://www.ncbi.nlm.nih.gov/pubmed/32691010
http://dx.doi.org/10.1016/j.omto.2020.06.009

Ejemplares similares